Erlotinib
Generic Details
Generic Name
Erlotinib
Other Names
- Tarceva
Drug Class
- Tyrosine Kinase Inhibitor
Chemical Formula
C22H23N3O4
Molecular Weight
393.44 g/mol
Mechanism of Action
- Inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR)
Indications
- Non-small cell lung cancer
- Pancreatic cancer
Common Dosage Forms
- Tablet
Typical Dosage
- 150mg/day on an empty stomach
Pediatric Dosage
Geriatric Dosage
Side Effects
- Rash
- Diarrhea
- Fatigue
- Anorexia
- Nausea
- Vomiting
Contraindications
- Hypersensitivity to erlotinib or any component of the formulation
Pregnancy Category
- Category D - Positive evidence of risk
Lactation Safety
- Lactation not recommended due to potential serious adverse reactions in breastfed infants
Drug Interactions
- Strong CYP3A4 inducers/inhibitors
Overdose Symptoms
- Diarrhea
- Rash
- Fatigue
Antidote for Overdose
Storage Conditions
- Store at room temperature (20-25°C)
- Protect from light and moisture
Pharmacokinetics
- Absorption: Oral bioavailability: ~60%
- Distribution: Highly protein bound (95%)
- Metabolism: Primarily by CYP3A4
- Excretion: Fecal (83%) and renal (13%)
Precautions
- Interstitial lung disease
- Hepatic impairment
Warnings
- Risk of severe skin reactions
- GI perforation
Others
- Avoid concomitant use of proton pump inhibitors (PPIs)